5th Oligonucleotides for CNS Summit 2025.

 

With clinical momentum from Eli Lilly’s lipidated brain shuttle siRNAs, Alnylam Pharmaceuticals’ ALN-APP siRNA, Wave’s Phase 1b/2a positive SELECT-HD data, 170+ biotech and 30+ pharma active in the field, and a surge of novel approaches, the oligonucleotide field shows no signs of slowing down.

The 5th Oligonucleotides for CNS Summit unites a select group of industry-leading biologists, chemists, C-level executives, platform tech experts, DMPK and clinical pharmacologists, all tackling the unique challenges of CNS delivered ASOs, siRNAs, miRNAs and saRNAs.

Hear from Alnylam Pharmaceuticals, Denali Therapeutics, Genentech, FDA, Novo Nordisk, Regeneron and more, to redefine the landscape of oligonucleotide research.

More Info

---

---